1. [Biomimetic electrochemical synthesis of quinol-thioether conjugates: their implication in the serotonergic neurotoxicity of amphetamine derivatives].
- Author
-
Largeron M, Neudorffer A, Gramond JP, and Fleury MB
- Subjects
- Amphetamines pharmacokinetics, Animals, Biotransformation, Electrochemistry, Hallucinogens pharmacokinetics, Hallucinogens toxicity, Humans, Hydroquinones toxicity, Molecular Mimicry, N-Methyl-3,4-methylenedioxyamphetamine pharmacokinetics, N-Methyl-3,4-methylenedioxyamphetamine toxicity, Sulfides toxicity, Amphetamines toxicity, Hydroquinones chemical synthesis, Neurotoxicity Syndromes pathology, Serotonin physiology, Sulfides chemical synthesis
- Abstract
Injection of 3,4-methylenedioxyamphetamine (MDA) or 3,4-methylenedioxymethylamphetamine (MDMA or ecstasy) directly into the brain fails to reproduce the long-term effects observed after peripheral administration, implying an essential role for systemic metabolites in the development of toxicity. However, the precise identity of the metabolites participating in MDA and MDMA-mediated serotonergic neurotoxicity remains unclear: neither 3,4-alpha-methyldopamine, nor N-methyl-alpha-methyldopamine, major metabolites, produce neurotoxicity following peripheral administration. In vivo, these metabolites are oxidized to the corresponding orthoquinones, that readily react with protein and nonprotein sulphydryls including glutathione (GSH). The resulting quinol-thioether conjugates exhibit a variety of toxicological activities, which can be regulated by intramolecular cyclisation reactions that occur subsequent to oxidation. The ability of quinol-thioether conjugates to redox cycle and produce reactive oxygen species provides a rationale for the potential role of these metabolites in MDA and MDMA neurotoxicity. A biomimetic one-pot synthesis of 5-(GSH-S-yl)-N-Me-alpha-Me-DA involving addition of GSH to the electrogenerated orthoquinone species, is reported to evaluate its in vivo potential neurotoxicity.
- Published
- 2003